4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide
C27H20F3N5O2 — CID 175731038
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide
4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide (PubChem CID 175731038) has the molecular formula C27H20F3N5O2 and a molecular weight of 503.48 g/mol. Its IUPAC name is 4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide.
Molecular Properties
| Compound Name | 4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide |
|---|---|
| PubChem CID | 175731038 |
| Molecular Formula | C27H20F3N5O2 |
| Molecular Weight | 503.48 g/mol |
| Exact Mass | 503.16 |
| IUPAC Name | 4-[[3-(3-methyl-4-oxoquinazolin-6-yl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]benzamide |
| SMILES | Cn1cnc2ccc(-c3cc(-c4ccc(C(F)(F)F)cc4)n(Cc4ccc(C(N)=O)cc4)n3)cc2c1=O |
| InChI | InChI=1S/C27H20F3N5O2/c1-34-15-32-22-11-8-19(12-21(22)26(34)37)23-13-24(17-6-9-20(10-7-17)27(28,29)30)35(33-23)14-16-2-4-18(5-3-16)25(31)36/h2-13,15H,14H2,1H3,(H2,31,36) |
| InChIKey | ROUIMISKYLACEU-UHFFFAOYSA-N |
| XLogP | 4.63 |
| TPSA | 95.80 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 503.48 |
| LogP ≤ 5 | 4.63 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175731038 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.